Tests ALTO-207 against placebo in adults with treatment-resistant depression
Tests whether ALTO-207 affects depression symptoms in adults with treatment-resistant depression.
Plain-language title generated from the registry record
Registry title: ALTO-207 in Adults With Treatment-resistant Depression (TRD)
Key facts
- Where
- Antrim, Birmingham, Bristol, Cardiff, Exeter, London, Nottingham, Oxford, Prescot, and Sheffield, United KingdomSee the 10 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07553637, who can take part
Where in United Kingdom
- AntrimAntrim, United KingdomNot yet recruiting
- BirminghamBirmingham, United KingdomNot yet recruiting
- BristolBristol, United KingdomNot yet recruiting
- CardiffCardiff, United KingdomNot yet recruiting
- ExeterExeter, United KingdomNot yet recruiting
- LondonLondon, United KingdomNot yet recruiting
- NottinghamNottingham, United KingdomNot yet recruiting
- OxfordOxford, United KingdomNot yet recruiting
- PrescotPrescot, United KingdomNot yet recruiting
- SheffieldSheffield, United KingdomNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alto Neuroscience
- Trial code
- NCT07553637
- Record updated
- 26 October 2026
- Original description
The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.Read full original descriptionShow less
A Randomized, Double-blind, Placebo-controlled Trial of ALTO-207 in Adults With Treatment-resistant Depression
The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.
Inclusion: Male and female participants, ages 18 to 75 years, inclusive, at the time of signing the ICF; Prior diagnosis of MDD without psychotic symptoms (in the current episode) and have confirmatory diagnosis of current MDD (moderate to severe); Failure to respond (<50% improvement) to at least 2-5 antidepressant treatments (including the current treatment); Currently taking a stable dose of at least 1 but no more than 2 oral antidepressants at baseline.
Exclusion: Concurrent use of any prohibited medications or substance use disorder; Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device; Evidence of unstable medical condition; Diagnosed bipolar disorder or a psychotic disorder or symptoms; Significant current PTSD symptoms or history of PTSD; Has a history of hypersensitivity or allergic reaction to ALTO-207 or any of its components/excipients; Clinically significant current impulse control difficulties.